Levact

Bendamustine hydrochloride, the active ingredient in Levact, is an alkylating agent presented as an intravenous formulation for use in cancer chemotherapy. It is used to treat certain types of blood cancers such as chronic lymphocytic leukemia, non‑Hodgkin lymphoma and mantle‑cell lymphoma in adult patients.

GNH USA supplies Levact as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Levact (bendamustine hydrochloride) is used in the treatment of hematologic malignancies.

- Chronic lymphocytic leukemia (CLL): improves disease control and prolongs survival in adult patients. - Non‑Hodgkin lymphoma (NHL): induces remission and reduces tumor burden in eligible patients. - Mantle‑cell lymphoma: achieves response rates and extends progression‑free survival in treated individuals.

Bendamustine may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset of the stomach. - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to easy bruising. - Anemia: decreased red blood cells causing weakness. - Fever: often associated with neutropenic infections.

Serious or Rare Side Effects: - Severe infections: opportunistic or bacterial infections requiring hospitalization. - Secondary malignancies: rare development of new cancers. - Pulmonary toxicity: interstitial lung disease or pneumonitis. - Hypersensitivity reactions: anaphylaxis or severe skin rash. - Tumor lysis syndrome: rapid tumor breakdown causing metabolic disturbances.

When using Levact, clinicians should observe several safety measures.

- Dose adjustment: monitor complete blood counts and modify dose based on hematologic toxicity. - Infection risk: assess for active infections before each infusion and treat promptly. - Renal function: evaluate renal impairment and consider dose reduction if necessary. - Hepatic function: monitor liver enzymes in patients with hepatic disease. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women unless benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Bendamustine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concurrent use with other alkylating agents: increased myelosuppression. - Live vaccines: heightened risk of severe infection. - Strong CYP3A4 inhibitors: may raise plasma bendamustine levels. - Radiation therapy: enhanced tissue toxicity when combined.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., fluconazole): may increase toxicity; monitor blood counts. - Hematopoietic growth factors (e.g., G‑CSF): may affect neutrophil recovery; adjust dosing. - Other cytotoxic agents: overlapping toxicities; monitor organ function.